Claims:

- A solid oral pharmaceutical composition comprising an effective amount of an acid sensitive active agent and a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition.
- 2. A solid oral pharmaceutical composition comprising an effective amount of an active agent which is poorly soluble in aqueous media and a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition.
- 3. A pharmaceutical composition according to claim 1 or 2 wherein the active agent has a solubility in aqueous media less than 1%.
- 4. A pharmaceutical composition according to any of claims 1 to 3 wherein the active agent is a serotonergic compound.
- 5. A pharmaceutical composition as claimed in any preceding claim wherein the active agent is a 5-HT₄ receptor antagonist.
- 6. A pharmaceutical composition as claimed in any of claims 1 to 4 wherein the active agent is a 5-HT₄ receptor agonist.
- 7. A pharmaceutical composition according to claim 6 wherein the 5-HT₄ receptor agonist is Tegaserod, preferably its hydrogen maleate (hml) salt.
- 8. A pharmaceutical composition as claimed in any preceding claim wherein the disintegrant is crospovidone.
- A pharmaceutical composition as claimed in any preceding claim comprising a lubricant.
- 10. A pharmaceutical composition according to claim 9 wherein the lubricant comprises a glyceryl mono fatty acid.

- 11. A pharmaceutical composition according to claim 9 wherein the lubricant comprises a mixture of glyceryl monostearate and polyethylene glycol.
- A pharmaceutical composition as claimed in any preceding claim comprising a surfactant.
- 13. A pharmaceutical composition according to claim 12 wherein the surfactant comprises poloxamer.
- 14. Use of at least 15% by weight of a disintegrant in the manufacturing of a solid pharmaceutical composition for the administering of an acid sensitive active agent.
- 15. Use of at least 15% by weight of a disintegrant in the manufacturing of a solid pharmaceutical composition for the administering of an active agent being acid sensitive and/or having a poor water solubility.
- 16. Use according to claim 14 or 15 wherein the active agent is a 5-HT₄ receptor agonist.
- 17. Use according to claim 16 wherein the 5-HT₄ receptor agonist is Tegaserod, preferably its hydrogen maleate salt.
- 18. Use of a pharmaceutical composition according to any one of claims 1 to 13 for the the manufacture of a composition for the prevention and treatment of gastro-intestinal motility disorders in humans or animals.
- 19. A process for improving dissolution properties of a pharmaceutical composition as claimed in any of claims 1 to 13.
- 20. A method for preventing, modulating or treating visceral pain or discomfort, for modulating visceral sensitivity or perception, for improving sensory perception of rectal distension, or for treating anal continence dysfunctions in a subject in need thereof, which method comprises administering to said subject an effective amount of a 5-HT₄

receptor agonist, partial agonist or antagonist or a pharmaceutically acceptable salt thereof.

- 21. A 5-HT₄ receptor agonist, partial agonist or antagonist or a pharmaceutically acceptable salt thereof for use in the manufacture of a pharmaceutical composition for use in preventing, modulating or treating visceral pain or discomfort, modulating visceral sensitivity or perception, improving sensory perception of rectal distension, or treating anal continence dysfunctions.
- 22. A pharmaceutical composition for use in preventing, modulating or treating visceral pain or discomfort, modulating visceral sensitivity or perception, improving sensory perception of rectal distension, or treating anal continence dysfunctions, which composition comprises a 5-HT₄ receptor agonist, partial agonist or antagonist or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable diluents or carriers therefor.
- 23. A method for preventing or treating gastro-intestinal motility disorders in horses or cattle in need thereof, which method comprises administering to the horses or cattle an effective amount of a 5-HT₄ receptor agonist or partial agonist or a pharmaceutically acceptable salt thereof.
- 24. A 5-HT₄ receptor agonist or partial agonist or a pharmaceutically acceptable salt thereof, for use as a veterinary pharmaceutical or for use in the manufacture of a veterinary pharmaceutical.
- 25. A pharmaceutical composition for veterinary use comprising a 5-HT₄ receptor agonist or partial agonist or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier therefor.
- 26. A pharmaceutical composition comprising Tegaserod having dissolution characteristics in water or USP buffers pH 6.8 and 7.5 of :

time (minutes)	amount (percentage)
5	30 - 90
15	80 - 100
30	95 - 100
60	100